Multiple Sclerosis

Discover how biomarkers like neurofilament light chain and glial fibrillary acidic protein enhance personalized care for patients who have multiple sclerosis.

Navigating treatment for multiple sclerosis and comorbid inflammatory diseases presents unique challenges, requiring careful, interdisciplinary strategies for optimal patient care.

Research highlights a strong link between Epstein-Barr virus and multiple sclerosis (MS), suggesting new therapeutic strategies targeting the virus for MS treatment.

A recent study reveals that over one-third of individuals with relapsing-remitting multiple sclerosis (MS) do not fully recover from relapses, highlighting critical recovery factors.

A study reveals that nearly 80% of US neurologists prescribing multiple sclerosis (MS) therapies received industry payments, influencing their prescribing patterns significantly.

New insights reveal how early intervention in radiologically isolated syndrome can delay multiple sclerosis (MS) onset and improve patient outcomes.

New findings demonstrate an association between increased cumulative depression genetic burden and multiple sclerosis (MS) disease activity.

Real-world studies reveal limited insights on infection risks for multiple sclerosis patients using disease-modifying treatments, highlighting gaps in clinical trial data.

Panelists discuss how providers and payers must collaborate to develop innovative coverage criteria for BTK inhibitors that prevent patients with subclinical progression from being forced to fail multiple inappropriate therapies before accessing optimal treatment.

Innovative therapies, including BTK inhibitors, target multiple sclerosis progression, offering hope for improved treatment outcomes and myelin repair.

Panelists discuss how academic centers can use telehealth programs like Project ECHO to train community neurologists and ensure consistent, evidence-based MS care across diverse geographic regions.

Panelists discuss how economic models must account for the broader impact of MS progression on earning potential, family planning, caregiver burden, and quality of life rather than focusing solely on direct medical costs.

Discover the latest advancements in multiple sclerosis (MS) treatment, including innovative therapies and strategies for disease prevention and repair.

Panelists discuss how patient-reported outcomes are crucial for capturing MS symptoms like fatigue, depression, and cognitive decline that significantly impact working-age patients but require standardization for practical clinical integration.

Panelists discuss how clinical trials and real-world studies should focus on patients with PIRA who haven’t experienced relapses for extended periods but continue to accumulate disability.

Discover the latest insights on pediatric-onset multiple sclerosis, emphasizing early intervention and high-efficacy therapies for improved outcomes in children.

Panelists discuss how the evaluation process must evolve to accommodate therapies that show benefits in slowing atrophy and motor decline over 1 to 2 years, emphasizing the need for early coverage rather than waiting for extensive long-term data.

Panelists discuss how disability progression can be measured through practical clinical tools like patient-reported outcomes, timed walking tests, and dexterity assessments rather than relying solely on relapse rates.

New biomarkers enhance multiple sclerosis (MS) diagnosis, enabling earlier detection and improved patient care, transforming MS management across the health care system.

Pediatric patients with multiple sclerosis (MS) face significant challenges transitioning to adult care, risking treatment delays and long-term health outcomes.

Vaccination against COVID-19 is crucial for individuals with multiple sclerosis (MS), ensuring safety and effectiveness despite immunosuppressive therapies.

Advancements in B-cell therapies, including anti-CD20 and anti-CD19 monoclonal antibodies, enhance treatment efficacy and safety for multiple sclerosis and autoimmune diseases.

The findings indicate that the currently approved 600-mg dose of intravenous ocrelizumab is optimal to significantly slow disability progression for patients with multiple sclerosis (MS).

National MS Education and Awareness Month is celebrated each year in the US in March, after having been launched in 2003 by MS Focus: the Multiple Sclerosis Foundation and affiliated groups.

In 2025, each issue of Population Health, Equity & Outcomes will feature a profile of a health system leader transforming care in their area of expertise. This issue spotlights a conversation with Kavita V. Nair, PhD, of the University of Colorado Anschutz Medical Campus.